Skip to content

News & Resources

Featured Stories

Pepperdine Graziadio Business School
Siren Biotechnology named a 2025 Most Fundable Company Read More
Media Coverage | Posted on 9.26.25
Siren Biotechnology named a 2025 Most Fundable Company
Press Releases | Posted on 5.12.25
Siren Biotechnology to Present Universal AAV Immuno-Gene Therapy Data at the 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
Biopharma Dive
Media Coverage | Posted on 5.11.25
Siren, a gene therapy startup, tests unconventional alternative to venture funding
Genetic Engineering & Biotechnology News
Media Coverage | Posted on 5.10.25
Signal Alert: Startup Seeks Community Funders for AAV Immuno-Gene Therapy
Media Coverage | Posted on 4.16.25
Siren community investment round featured in BiotechTV
Media Coverage | Posted on 4.16.25
Siren Biotechnology Opens Community Investment Round!
San Francisco Business Times
Media Coverage | Posted on 4.3.25
Siren CEO and Founder Dr. Nicole Paulk named in SFBT Women to Watch
Media Coverage | Posted on 4.3.25
Siren Biotechnology Presents at SXSW 2025
Press Releases | Posted on 3.4.25
Siren Biotechnology Expands Clinical and Scientific Advisory Board with Key Industry Leaders
Media Coverage | Posted on 1.9.25
Siren Biotechnology named 2025 Company to Watch by Slice of Healthcare